Radiation Therapy in Oligometastatic Prostate Cancer

Int J Radiat Oncol Biol Phys. 2022 Nov 15;114(4):684-692. doi: 10.1016/j.ijrobp.2022.07.014. Epub 2022 Jul 22.

Abstract

Prostate cancer ranges from localized, low risk to metastatic, morbid disease. Although radiation therapy (RT) is commonly incorporated in the treatment of early disease or for palliation of symptomatic lesions, its role in extending survival in metastatic disease is less well-established. Here, we review the available evidence surrounding localized RT in the presence of oligometastatic disease and metastasis-directed therapy in both hormone-sensitive and hormone-resistant prostate cancer. We further outline potential future incorporation of RT as an immune-sensitizing therapy and the importance of highly sensitive imaging modalities in considering RT in metastatic disease.

Publication types

  • Review
  • Research Support, N.I.H., Extramural

MeSH terms

  • Hormones
  • Humans
  • Male
  • Neoplasm Metastasis / radiotherapy
  • Prostatic Neoplasms* / diagnostic imaging
  • Prostatic Neoplasms* / pathology
  • Prostatic Neoplasms* / radiotherapy
  • Radiosurgery* / methods

Substances

  • Hormones